T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.
T&R Biofab Co. Ltd (246710) - Net Assets
Latest net assets as of September 2025: ₩11.31 Billion KRW
Based on the latest financial reports, T&R Biofab Co. Ltd (246710) has net assets worth ₩11.31 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩83.86 Billion) and total liabilities (₩72.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩11.31 Billion |
| % of Total Assets | 13.48% |
| Annual Growth Rate | 23.67% |
| 5-Year Change | -47.43% |
| 10-Year Change | N/A |
| Growth Volatility | 86.9 |
T&R Biofab Co. Ltd - Net Assets Trend (2015–2024)
This chart illustrates how T&R Biofab Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for T&R Biofab Co. Ltd (2015–2024)
The table below shows the annual net assets of T&R Biofab Co. Ltd from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩24.21 Billion | -22.39% |
| 2023-12-31 | ₩31.20 Billion | -20.54% |
| 2022-12-31 | ₩39.26 Billion | -5.83% |
| 2021-12-31 | ₩41.69 Billion | -9.47% |
| 2020-12-31 | ₩46.05 Billion | +86.02% |
| 2019-12-31 | ₩24.76 Billion | -18.20% |
| 2018-12-31 | ₩30.27 Billion | +233.66% |
| 2017-12-31 | ₩9.07 Billion | +2.50% |
| 2016-12-31 | ₩8.85 Billion | +147.54% |
| 2015-12-31 | ₩3.58 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to T&R Biofab Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13647455822000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩10.77 Billion | 44.50% |
| Other Components | ₩151.77 Billion | 626.86% |
| Total Equity | ₩24.21 Billion | 100.00% |
T&R Biofab Co. Ltd Competitors by Market Cap
The table below lists competitors of T&R Biofab Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Danen Technology Corp
TW:3686
|
$38.94 Million |
|
Pontex Polyblend Co.Ltd
TWO:8935
|
$38.94 Million |
|
SebitChem Co. Ltd.
KQ:107600
|
$38.95 Million |
|
Indonesia Energy
NYSE MKT:INDO
|
$38.95 Million |
|
Alpha Pro Tech Ltd
NYSE MKT:APT
|
$38.91 Million |
|
Lument Finance Trust Inc
NYSE:LFT
|
$38.90 Million |
|
DP Aircraft I Limited
LSE:DPA
|
$38.90 Million |
|
Omega Oil & Gas Ltd
AU:OMA
|
$38.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in T&R Biofab Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,197,256,940 to 24,211,060,300, a change of -6,986,196,640 (-22.4%).
- Net loss of 7,678,779,260 reduced equity.
- Share repurchases of 4,834,173,210 reduced equity.
- New share issuances of 4,834,173,210 increased equity.
- Other factors increased equity by 692,582,620.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-7.68 Billion | -31.72% |
| Share Repurchases | ₩4.83 Billion | -19.97% |
| Share Issuances | ₩4.83 Billion | +19.97% |
| Other Changes | ₩692.58 Million | +2.86% |
| Total Change | ₩- | -22.39% |
Book Value vs Market Value Analysis
This analysis compares T&R Biofab Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.26x to 2.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩731.29 | ₩3115.00 | x |
| 2017-12-31 | ₩700.41 | ₩3115.00 | x |
| 2018-12-31 | ₩1858.70 | ₩3115.00 | x |
| 2019-12-31 | ₩1482.88 | ₩3115.00 | x |
| 2020-12-31 | ₩2731.15 | ₩3115.00 | x |
| 2021-12-31 | ₩2016.11 | ₩3115.00 | x |
| 2022-12-31 | ₩1852.51 | ₩3115.00 | x |
| 2023-12-31 | ₩1449.43 | ₩3115.00 | x |
| 2024-12-31 | ₩1123.65 | ₩3115.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently T&R Biofab Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -157.55%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 4.07x
- Recent ROE (-31.72%) is below the historical average (-29.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -34.69% | -1696.46% | 0.01x | 1.52x | ₩-1.60 Billion |
| 2016 | -34.12% | -1101.30% | 0.03x | 1.08x | ₩-3.90 Billion |
| 2017 | -44.74% | -1000.66% | 0.04x | 1.04x | ₩-4.97 Billion |
| 2018 | -15.51% | -481.71% | 0.03x | 1.03x | ₩-7.72 Billion |
| 2019 | -25.25% | -485.66% | 0.05x | 1.09x | ₩-8.73 Billion |
| 2020 | -12.17% | -82.36% | 0.14x | 1.05x | ₩-10.21 Billion |
| 2021 | -26.58% | -342.64% | 0.04x | 1.97x | ₩-15.25 Billion |
| 2022 | -26.33% | -179.63% | 0.08x | 1.93x | ₩-14.26 Billion |
| 2023 | -43.01% | -258.10% | 0.05x | 3.20x | ₩-16.54 Billion |
| 2024 | -31.72% | -157.55% | 0.05x | 4.07x | ₩-10.10 Billion |
Industry Comparison
This section compares T&R Biofab Co. Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $98,321,642,752
- Average return on equity (ROE) among peers: 7.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| T&R Biofab Co. Ltd (246710) | ₩11.31 Billion | -34.69% | 6.42x | $38.93 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |